Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Reduce” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given a consensus recommendation of “Reduce” by the nine ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and eight have given a hold recommendation to the company.

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $6.80 on Thursday. The stock has a market cap of $26.72 billion, a P/E ratio of -18.89 and a beta of 1.08. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The stock’s 50-day moving average is $7.62 and its 200-day moving average is $7.47. Bayer Aktiengesellschaft has a 1-year low of $6.74 and a 1-year high of $11.34.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Tuesday, August 6th. The company reported $0.25 EPS for the quarter, meeting the consensus estimate of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The business had revenue of $12 billion for the quarter. Equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.